Kornimate/medical-research-clean huggingface dataset:
the effect of laughter yoga practiced before simulation training

Conditions: Laughter; State Anxiety; Stress; Self Confidence; Satisfaction, Personal

Summary: simulation education has become one of the innovative educational approaches that are widely used in providing nursing students with knowledge, skills, and attitudes towards vocational courses. simulation education provides students with the opportunity to combine their knowledge and skills and provide nursing care in a high-reality environment. however, the fact that simulation training is a method that requires the student to recognize a clinical event, make a clinical decision, and intervene with the patient in line with this decision may cause students to experience anxiety and affect their learning. although there are limited studies conducted on nursing students, it is stated that new approaches such as laughter yoga are effective in reducing anxiety and stress levels. in this direction, this research; in this study, it was planned to investigate the effectiveness of laughter yoga in terms of reducing the anxiety experienced by nursing students during simulation training and increasing their learning satisfaction. the universe of the research will be the second-year students of hacettepe university faculty of nursing. as a result of the power analysis, it is aimed to reach 54 people. the study was planned in a randomized controlled design. research data will be collected through personal information form, state anxiety scale, student satisfaction and self-confidence in learning scale, perceived stress scale for nursing students, and students' vital findings evaluation form. with this study, it is predicted that laughter yoga to be applied to nursing students before simulation training will have a positive effect on state anxiety, student satisfaction, and perceived stress level.

the study will be carried out in a randomized controlled design with the aim of determining the effect of laughter yoga applied before the simulation training on the state anxiety, student satisfaction, and perceived stress level of nursing students. after the power analysis to calculate the sample size of the study, a total of 36 students will be included in each group with 90% power and 5% margin of error for multiple variance analysis in repeated measurements in a 2x2 factorial pattern between groups. in the research, students who have applied laughter yoga and simulation application together will form the intervention group, and students who only participated in the simulation application will form the control group.

Eligibility criteria:
inclusion criteria: * 18 years and over, * students who voluntarily agree to participate in the research will be included in the research. exclusion criteria: * taking any medication that affects the heart rate, * having any psychiatric disease such as anxiety disorder, * students who do not accept to participate in the research will not be included in the research.
semantic memory, financial capacity, and brain perfusion in mild cognitive impairment (mci) (casl)

Conditions: Alzheimer Disease; Dementia

Summary: alzheimer's disease (ad) often manifests as a memory disorder before dementia develops. dementia is considered to be present when a person can no longer handle complex activities of daily living, such as managing finances. this study will investigate the relationship between changes in the ability to manage finances and brain perfusion, which will be measured using continuous arterial spin-labeling (an experimental mri). subjects will also undergo neuropsychological tests focusing on several types of memory and thought process, with special emphasis on semantic memory. an important question to be addressed is whether changes in function are better predicted by the neuropsychological tests or by the brain scan.

alzheimer's disease (ad) often manifests as a memory disorder before dementia develops. dementia is considered to be present when a person can no longer handle complex activities of daily living, such as managing finances. this study will investigate the relationship between changes in the ability to manage finances and brain perfusion, which will be measured using continuous arterial spin-labeling (an experimental mri). subjects will also undergo neuropsychological tests focusing on several types of memory and thought process, with special emphasis on semantic memory. an important question to be addressed is whether changes in function are better predicted by the neuropsychological tests or by the brain scan. participants will undergo a single mri scan, baseline financial capacity instrument (fci) and cognitive evaluation, and then will be followed approximately annually to repeat the functional and cognitive assessments. linear mixed effects models will be used to fit a model predicting financial capacity based on baseline cognitive tests. measures from the mri scan will be added to the model to determine whether imaging improves the predictions.

Eligibility criteria:
inclusion criteria: * veteran or non-veteran * age 50-89 * with normal cognition or memory impairment (mci or mild ad) * english speaking * right handed * adequate vision and hearing to take part in tests * able and willing to undergo mri scan * medically and psychiatrically stable * no other brain disease (such as tumor, parkinson's disease, major stroke) exclusion criteria: * pregnancy * inability to tolerate mri (due to metal in body or claustrophobia)

Keywords: magnetic resonance imaging alzheimer disease mild cognitive impairment continuous arterial spin labeling semantic memory
phase ii study of myeloablative double unit umbilical cord blood transplantation in adult patients

Conditions: Hematologic Malignancy

Summary: this study aimed to evaluate the efficacy and safety of myeloablative double unit umbilical cord blood transplantation (ducbt) in adult patients with hematologic malignancies. two myeloablative conditioning regimens will be used in this study: (1) total body irradation (tbi), cyclophosphamide, and cytarabine, or (2) thiotepa, busulfan, and fludarabine.


Eligibility criteria:
inclusion criteria: * patients with hematologic malignancies requiring hematopoietic stem cell transplantation: (1) high risk acute myeloid leukemia in remission, (2) high risk acute lymphoblastic leukemia in remission, or (3) ipss intermediate-2, high, or transfusion-dependent myelodysplastic syndrome * patients who have suitable cord blood units for ducbt * patients with ecog performance status 0-1 * patients with adequate organ function: lung, kidney, liver, heart, etc. * informed consent exclusion criteria: * patients who can receive hematopoietic stem cell transplantation from hla-matched sibling or unrelated donors * patients who have anti-hla antibodies * patients with any evidence of central nervous system (cns) involvement of disease * patients with uncontrolled diabetes * patients with uncontrolled hypertension * patients with any evidence of active infection * positive for human immunodeficiency virus (hiv) * previous history of other malignancy within 5 years (basal cell carcinoma of skin, cervical carcinoma in situ, and differentiated thyroid carcinoma with curative resection are permitted.) * women who are pregnant or breastfeeding * patients with previous history of allogeneic stem cell transplantation * patients with major psychotic disorder or drug/alcohol abuser * inappropriate patients according to the investigators' opinion
personality type as a predictor to develop depression and reduction in quality of life among stroke survivals.

Conditions: Stroke; Depression; Quality of Life; Personality Type

Summary: personality type as a predictor to develop depression and reduction in quality of life among stroke survivals.


Eligibility criteria:
inclusion criteria: * any stroke, * age 40-90, * able to sigh informed concent, * able to fill in the questionnaires. exclusion criteria: * non stroke, * previous depression, * not able to give consent or answer the questions.
retina microvascular remodeling and cognitive function in hypertension

Conditions: Hypertension; Mild Cognitive Impairment

Summary: this study aims to determine the relationships between retina micro-vascular remodeling and cognitive function in hypertensive patients. the study plans to enrol 160 patients (100 patients with mild cognitive impairment -mci- and 60 without mci).

our project stands on physiopathological and cognitive angles, and is mainly based on the major role of large and small arteries elasticity on cognitive aging. it will benefit from the recent innovative accurate and non invasive techniques such as mri for central large arteries and adaptative optics for retina arterioles imaging. study population is the following: * 60 patients with hypertension and no mci, * 50 patients with hypertension and stable mci, without dementia * 50 patients with hypertension and progressive mci, without dementia every patients will perform a medical interview and examination, an mri (brain + aorta), adaptative optics imaging, a cognitive tests and a blood test. primary outcome is to determine the relationships between retina micro-vascular remodeling and cognitive function in this population.

Eligibility criteria:
inclusion criteria: 1. aged 65 or more 2. hypertension (bp ≥140/90 mmhg and/or antihypertensive treatment) 3. signed informed consent by the patient 4. sufficient mastery of the french language to perform neuropsychological tests exclusion criteria: 1. impossibility to visualize the retinal : severe cataract 2. dementia (defined by mmse\<20) 3. clinical stroke 4. severe or resistant hypertension 5. hypertension treated with more than 3 different pharmacological classes 6. any other disease that may interfere with the assessment of cognitive disorders (epilepsy, parkinson's disease, major depression, schizophrenia, manic-depressive) 7. enrolment in a therapeutic trial that could interfere with the main objective 8. less than 4 years of formal education 9. illiterate, unable to read, write or count 10. major physical problems that may interfere with the tests (sight, hearing, ...) 11. short term life threatening disease 12. non-affiliation to a healthcare system 13. consent refusal 14. contraindication to mri including claustrophobia, metallic devices, pacemaker, mechanical valve implanted before 1985, and nursing, as well as technical contra-indication: patient diameter \> 70 cm or/and weight \> 250 kg
effects of botulinum toxin type a in adults with cerebral palsy

Conditions: Cerebral Palsy

Summary: the purpose of this project is to investigate if there is a significant difference in active joint range of motion, questionnaire on gait function and health related quality of life between patients randomized to treatment with botulinum toxin type a and patients randomized to placebo treatment.

cerebral palsy (cp) is a constellation of symptoms and conditions defined as lifelong motor dysfunction resulting rom a non-progressive brain lesion occurring pre-, peri- or postnatal before the second year of life. cp consists of different aspect of motor disorder including spasticity, paresis, incoordination and dystonia there is scarce knowledge about the association between spasticity, pain and physical function in the adult cp-population, and the systematic follow up of patients with cp typically ends at the age of eighteen. frequently used intervention in spastic cerebral palsy for children with gait problems are injections with botulinum toxin type a (btx-a) in leg and thigh muscles, and three dimensional-gait analysis has become a standard procedure in treatment decision and evaluation. botulinum toxin a (btx- a) is a highly effective treatment in the management of spasticity. the first reported success of use of btx-a in children with cerebral palsy was made in 1993 by koman et al. subsequently, randomized controlled studies on children with spastic type of cerebral palsy has documented that btx-a is effective and safe in the management of muscle spasticity in children with cp. there is an implicit, and as of yet, unproven assumption that there is no indication for this treatment in the adult cp-population.

Eligibility criteria:
inclusion criteria: * unilateral or bilateral spastic cp * modified ashworth scale (mas) ≥ 2 in ankle- or knee joint muscles. * ≥ 18 year of age, ≤ 65 year of age * ambulant without walking aids minimum 10 metres in functional equines and/or with pathological knee extension or flexion pattern. exclusion criteria: * cognitive impairment. * no spasticity (mas \< 2 ) * \< 18 year of age * not ambulant without walking aids * pregnant or planning pregnancy * btx-a treatment last 6 months * orthopedic surgery lower extremity last 18 months * obvious skeletal/joint deformity where orthopedic surgery is indicated * other diseases which can affect level of function (rheumatoid or neurological ) * new treatment the past four weeks which affect the musculoskeletal system (pain killers, physical therapy, acupuncture)

Keywords: adult cerebral palsy spastic contractures botulinum toxin type a
physical exercise for patients who suffer from weight loss due to head and neck cancer undergoing medical treatment

Conditions: Head and Neck Cancer; Cachexia; Cancer; Resistance Training

Summary: cancer cachexia is a prevalent symptom of head and neck neoplasms. the reduction in skeletal muscle mass is one of the main characteristics which can lead to poor physical functioning. the purpose of this study was to determine the feasibility of progressive resistance training in cachectic head and neck cancer patients during radiotherapy in a pilot randomized controlled design. baseline data for all participants were ascertained via medical records and patient interview. this included demographic information, union internationale contre le cancer-status (uicc-status), comorbidities and the results of blood samples. outcomes were measured at admission. one study coordinator completed all assessments to enhance patient compliance. body weight loss percentage was calculated via the individuals' body weight 6 months before (in retrospect) and the current body weight. participants completed two questionnaires: the multidimensional fatigue inventory and the functional assessment of anorexia/cachexia therapy questionnaire. six-minute walk test was applied. to document changes in muscle force, strength of the functional muscle group for elbow flexion in supine position as well as of knee extension in sitting position (in each case right and left) was tested via hand-held dynamometry for isometric maximal muscle strength. bioelectrical impedance analysis was executed to assess the adaption in body composition. the exercise intervention was undertaken in the hospitals department of physical and rehabilitation medicine and based on standardized but individualized training protocols. it consisted of a warm up period for 5 minutes on a bicycle ergometer or an upper body cycle with individual selectable wattage. a leg press, a latissimus pull-down and a chest press formed the three equipment supported core exercises. all exercises were performed with 8-12 repetitions and 3 sets.


Eligibility criteria:
inclusion criteria: * planned inpatient or outpatient radiotherapy * ≥ 18 years of age * diagnosed state of cachexia (weight loss greater than 5 % over the past 6 months) or pre-cachexia (unintentional weight loss of 5 % or less of usual body weight during the last 6 months) exclusion criteria: * metastatic disease * severe neurological problems or other contraindications for resistance training
project engage: a wrist biosensor-based mhealth suite to support alcohol intervention in young people living with hiv

Conditions: HIV

Summary: in this study, participants will be asked to wear a wrist alcohol biosensor for 30 days and report alcohol use using a ecological momentary assessment (ema) app. a subset of the sample will be micro-randomized to test two engagement strategies--reciprocity and personalized feedback via the ewrapper app to promote their engagement with the biosensor.

yplwh (n = 160, 136 after 15% attrition, 18-29 years of age, estimated to include 73% male, 26% female, 1% transgender, 70% racial and ethnic minorities) will be asked to wear a wrist alcohol biosensor (bactrack skyn) for 30 days and report their alcohol use using daily ecological momentary assessment (ema). a subset of the sample will also be micro-randomized twice daily to test two empirically-based engagement strategies - reciprocity and personalized feedback. data from the 30-day mrt will be used to (a) develop and validate the algorithm for alcohol detection based on skyn data; and (b) address scientific questions concerning which engagement strategy works best, for whom and under what conditions in terms of facilitating proximal engagement in biosensor wearing. we will also collect alcohol biomarker (i.e., peth) at 1-month follow up.

Eligibility criteria:
inclusion criteria: * 18 years and 0 months to 29 years and 11 months * currently reside in florida * report having had at least 1 alcoholic drink in the last 30 days * able to read and understand english * have internet access via smartphone, tablet or computer * be diagnosed as hiv positive and; * willing to provide informed consent. exclusion criteria: * adults unable to consent * individuals who are not yet adults * individuals who are not diagnosed as hiv+ * prisoners * pregnant women
efficacy of biweekly ranibizumab (0.5 mg) for exudative macular degeneration retinal edema refractory to anti-vegf

Conditions: Exudative Age Related Macular Degeneration

Summary: this is a 24 week open label study to assess the efficacy of bi-weekly ranibizumab for patients with retinal fluid due to exudative macular degeneration refractory to monthly therapy.

this is a 24 week, open-label, non-randomized, phase ii study evaluating intravitreal ranibizumab dosed every 14 days in subjects with exudative macular degeneration who have persistent intraretinal or subretinal fluid despite chronic monthly anti-vegf therapy (\>6 months). subjects must have had a minimum of 5 intravitreal anti-vegf injections administered every 4-6 weeks in the 6 months preceding enrollment. consented, enrolled subjects will receive multiple open-label intravitreal injections of 0.5 mg ranibizumab administered every 14 days (± 3 days). subjects who have resolution of fluid will convert to monthly ranibizumab for the remainder of the study. if fluid recurs, subjects will return to biweekly treatment. patients will be assigned to receive treatment with either ranibizumab vial or pfss so that approximately 10 patients will be treated with each delivery method option, and syringe preparation time (spt) will be measured by an assistant who will be observing the procedure and timing with an automated stopwatch.

Eligibility criteria:
inclusion criteria: * age \> 50 years * exudative age related macular degeneration in study eye involving the fovea * best corrected visual acuity (by etdrs) letter score in study eye of \ 24 (approximate snellen equivalent 20/20 to 20/320) * persistent intraretinal or subretinal fluid on sd oct despite a minimum of 5 intravitreal anti-vegf injections administered every 4-6 weeks in the in the 6 months preceding enrollment in the study eye * at least 30 days from last intravitreal anti-vegf injection in the study eye exclusion criteria: * patient who are receiving systemic anti-vegf or proangiogenic therapy * patients on chronic high doses corticosteroid therapy (\> than 10 mg of oral prednisone or equivalent greater than 10 days) * patients on chronic immunosuppressant therapy * patients on drugs known to have toxic side effects on the retina e.g. hydroxychloroquine * history of intravitreal corticosteroids in study eye within 4 months of baseline * uncontrolled hypertension (defined as systolic \>180 mm hg and/or diastolic \> 100 mm hg while patient is sitting) * history of stroke or aptc event in the previous year * any intraocular surgery in study eye within 90 days of baseline * presence of vitreomacular traction in study eye * presence of significant epiretinal proliferation in study eye * evidence of active infection in either eye * uncontrolled glaucoma in the study eye defined as a pressure \> 25 mmhg on maximal medical therapy

Keywords: macular degeneration amd wet amd lucentis
study to assess gtaexs617 in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: a phase 1/2 study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of gtaexs617-001 in patients with advanced solid tumors.

a phase 1/2 study to assess the safety, tolerability, pharmacokinetics and anti-tumor activity of gtaexs617-001 as monotherapy and in combination, in patients with one of the following advanced solid tumors: head and neck squamous cell carcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, breast cancer (hr+ and her2- that has progressed to a prior treatment with cd4/cdk6 inhibitor), ovarian epithelial carcinoma.

Eligibility criteria:
inclusion criteria: * ecog performance status 0-1 * life expectancy \>3 months * one the following histologically or cytologically confirmed advanced solid tumors: head and neck squamous cell carcinoma, colorectal adenocarcinoma, pancreatic adenocarcinoma, nsclc, breast carcinoma (hr+ and her2- that has progressed to a prior treatment with cd4/cdk6 inhibitor), or ovarian epithelial carcinoma * patients must have disease that is advanced (ie, surgery or radiotherapy are not considered to be potentially curative), recurrent, or metastatic following soc treatments * adequate hematological, liver, and renal function * participant must have tumor lesion(s) or metastases amenable to biopsy, excluding bone metastases exclusion criteria: * active and clinically significant (cs) infection * refractory nausea and/or vomiting, chronic gastrointestinal disease, or previous significant bowel resection, with cs sequelae that would preclude adequate absorption of gtaexs617 * symptomatic central nervous system (cns) malignancy or metastases * concurrent active or previous malignancy * prior organ or allogeneic stem-cell transplantation * moderate or severe cardiovascular disease * received anticancer therapy within 28 days or 5 half-lives (whichever is shorter) before the first dose of the study treatment * received treatment with known strong inhibitors and or inducers of cytochrome p450 3a isoform subfamily (cyp3a) within 14 days or 5 half-lives before the first dose of study treatment * received treatment with known inhibitors or inducers of p-glycoprotein (p-gp) or breast cancer resistance protein (bcrp) within 14 days or 5 half-lives before the first dose of study * received treatment with known substrates of organic anion transporting peptide 1b3 (oatp1b3) or bcrp within 14 days or 5 half-lives before the first dose of study treatment * unresolved or unstable serious toxic side-effects of prior chemotherapy or radiotherapy * has had or is scheduled to have major surgery \<28 days prior to the first dose of study treatment